Carolyn L. Cannon, MD, PhD
- Pulmonary Medicine
Associate Professor of Pediatrics, Section of Pediatric Pulmonology, Baylor College of Medicine
Associate Professor of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, College of Medicine
Associate Director, Texas A&M University MD/PhD Program, Texas A&M University Health Science Center, College of Medicine
Phone:
832-822-3300
Languages: English
Departments:
Office location:
Texas Medical Center
6701 Fannin Street
Houston, TX 77030
Get to know Carolyn L. Cannon, MD, PhD
Clinical Interests
Dr. Cannon is a physician-scientist with over 15 years of experience caring for children with lung disease, particularly lung disease related to cystic fibrosis. She has served as the director of pediatric Cystic Fibrosis Centers at two hospitals and initiated the Cystic Fibrosis Therapeutic Development Center in one hospital participating as the site principle investigator for clinical trials.
Education
| School | Education | Degree | Year |
|---|---|---|---|
| Boston Children's Hospital | Fellowship | Pediatric Pulmonology | 1999 |
| Channing Lab, Harvard Medical School | Postgraduate Training | Microbiology | 1999 |
| Boston Children's Hospital | Residency | Pediatrics | 1996 |
| University of Texas Health Science Center | PhD | Doctor of Philosophy | 1993 |
| The University of Texas Medical School at Houston | Medical School | Doctor of Medicine | 1993 |
| Worcester Polytechnic Institute | Masters | Master of Science in Electrical Engineering | 1985 |
Organizations
| Organization Name | Role |
|---|---|
| Harris County Medical Society | Member |
| American Thoracic Society | Member; Member of the Pediatric Planning Committee |
| American Society for Microbiology | Member |
| American Chemical Society | Member |
* Texas Children’s Hospital physicians’ licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician’s office and were not verified by Texas Children’s Hospital.
Research interests
Dr. Cannon’s research focuses on the development of aerosolized formulations, including nanoparticle formulations, of novel antimicrobials to treat lung infections in patients with cystic fibrosis. For example, she has served as a Project Leader for an NHLIBI funded Program of Excellence in Nanotechnology (PEN). The project focused on development of nanoparticle delivery devices to treat Pseudomonas aeruginosa lung infections.
Shah PN,* Marshall-Batty KR,* Smolen JA, Tagaev JA, Chen Q, Rodesney CA, Le HH, Gordon VD, Greenberg DE, Cannon CL. Antimicrobial activity of ibuprofen against cystic fibrosis associated Gram-negative pathgens. Antimicrobial Agents and Chemotherapy 2018; 62: e01574-17; *co-first author.
Lahiri T, Hempstead SE, Brady C, Cannon CL, Clark K, Condren ME, Guill MF, Guillerman RP, Leone CG, Maguiness K, Monchil L, Powers SW, Rosenfeld M, Schwarzenberg SJ, Tompkins CL, Zemanick ET, Davis SD. Clinical Practice Guidelines from the Cystic Fibrosis Foundation for preschoolers with cystic fibrosis. Pediatrics 2016; 137(4): e20151784.
Wainwright CE, et. al; TRAFFIC and TRANSPORT Study Groups. Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. New England Journal of Medicine 2015; 373:220-231. PMC4764353.
Shah PN, Lin LY, Smolen JA, Tagaev JA, Gunsten SP, Han DS, Heo GS, Li Y, Zhang F, Zhang S, Wright BD, Panzner MJ, Youngs WJ, Brody SL, Wooley KL,* Cannon CL.* Synthesis, characterization, and in vivo efficacy of shell crosslinked nanoparticle formulations carrying silver antimicrobials as aerosolized therapeutics. ACS-Nano 2013; Jun 25;7(6):4977-87; *co-last author. PMC4287418.